Peptide therapy in Texas has gone from a fringe wellness topic to one of the fastest-growing requests at medical clinics across the state. Patients are asking about it in Dallas waiting rooms, Fort Worth medspa consultations, and Austin telehealth calls. The reasons are real, and the demand has surged alongside interest in weight management, anti-aging, and cellular health optimization.
But the landscape has shifted significantly. Twelve peptides were formally removed from the FDA’s Category 2 restricted list on April 23, 2026. The FDA’s Pharmacy Compounding Advisory Committee is scheduled to review seven of those peptides on July 23-24, 2026. This meeting will determine which compounds licensed compounding pharmacies can legally prepare under physician prescription going forward.
This guide has been updated to reflect the current regulatory picture, current pricing at InjectCo, and what patients searching for BPC-157, CJC-1295, and other previously restricted peptides need to know right now.
Peptides are short chains of amino acids. Your body makes them naturally. They act as chemical messengers, telling your cells to produce more collagen, release growth hormones, repair tissue, or support your immune response. Think of them as very specific instruction signals. The problem is that your body produces fewer of them as you age.
Peptide therapy involves using lab-synthesized versions of these compounds, administered under physician supervision, to support specific biological functions. This can range from stimulating growth hormone release to boosting cellular energy production to supporting skin health from the inside out.
The key word here is ‘support.’ Peptides are not drugs in the traditional sense. They do not force your body to do something it would not otherwise do. They prompt natural processes that may have slowed down.
Peptide therapy programs address a wide range of goals. Here’s where current clinical use is most common:
Not all peptide therapy looks the same. Here’s how it breaks down by delivery method and clinical classification:
Injectable peptides are absorbed directly into the bloodstream. This gives them the most consistent bioavailability. Sermorelin, GHK-Cu, NAD+, and glutathione are commonly administered this way.
Oral and sublingual peptides are an emerging category. GLP-1 medications are now available in oral tablet form. Sublingual drops, like those offered at some Texas clinics, absorb through the lining of the mouth. Bioavailability varies depending on the compound and formulation.
Medical-grade vs. non-medical peptides is where things get complicated. Medical-grade compounded peptides come from licensed 503A or 503B pharmacies and require a physician’s prescription. On the other hand, research peptides are sold online without a prescription under the guise of laboratory use. The quality control, sterility, and dosing accuracy of research peptides is not regulated and poses real safety risks.
This is the most-searched question in the peptide space right now, and the answer has changed meaningfully in the weeks since our April 2026 update.
The short version: peptide therapy in Texas is legal when prescribed by a licensed physician and dispensed through a licensed compounding pharmacy. What that means in practice depends on which specific peptide you are asking about.
On April 23, 2026, the FDA formally removed 12 peptides from its Category 2 restricted list. These peptides had been placed on the restricted list in late 2023, effectively preventing licensed compounding pharmacies from preparing them. The April 23 removal includes compounds that patients in Texas have been asking about most:
| Peptide | Category 2 Removed? | PCAC July Review? | Can Compound Now? |
| BPC-157 | Yes (Apr 23, 2026) | Yes (July 23) | NOT YET (pending PCAC) |
| TB-500 | Yes (Apr 23, 2026) | Yes (July 23) | NOT YET (pending PCAC) |
| KPV | Yes (Apr 23, 2026) | Yes (July 23) | NOT YET (pending PCAC) |
| MOTS-C | Yes (Apr 23, 2026) | Yes (July 23) | NOT YET (pending PCAC) |
| Semax | Yes (Apr 23, 2026) | Yes (July 24) | NOT YET (pending PCAC) |
| Epitalon | Yes (Apr 23, 2026) | Yes (July 24) | NOT YET (pending PCAC) |
| Emideltide (DSIP) | Yes (Apr 23, 2026) | Yes (July 24) | NOT YET (pending PCAC) |
| GHK-Cu (injectable) | Yes (Apr 23, 2026) | No (separate track) | Status unclear (ask provider) |
| CJC-1295 | Expected | Expected later 2026 | Not yet confirmed |
| Ipamorelin | Expected | Expected later 2026 | Not yet confirmed |
| Sermorelin | Was not restricted | N/A | YES (available now) |
| NAD+ | Was not restricted | N/A | YES (available now) |
| Glutathione | Was not restricted | N/A | YES (available now) |
| GLP-1 (semaglutide) | Was not restricted | N/A | YES (available now) |
| Melanotan II | Remains restricted | Not scheduled | NO |
| GHRP-2 | Remains restricted | Not scheduled | NO |
| GHRP-6 | Remains restricted | Not scheduled | NO |
Removal from Category 2 is not the same as compounding clearance. This is where most of the confusion and misinformation in the peptide space comes from.
The process works like this: the FDA’s Pharmacy Compounding Advisory Committee (PCAC) must review each substance and make a recommendation. The FDA then issues a formal rule change. Only after that formal rule change can licensed 503A compounding pharmacies legally prepare and dispense that compound to patients under a physician’s prescription.
The PCAC meeting scheduled for July 23-24, 2026 is the next major step in that process. For BPC-157, TB-500, and the other peptides on the July agenda, the meeting will produce recommendations. Formal rulemaking follows after.
If a provider today is telling you BPC-157 is ‘available again’ or ‘back to legal,’ ask them specifically which pharmacy is dispensing it and under what regulatory authority. A compliant provider can answer this clearly.
The legal line has not changed even as the regulatory picture evolves. Prescription peptides come from licensed 503A or 503B compounding pharmacies. They require a valid physician’s order and undergo quality control testing.
Research peptides are a different category entirely. They are sold online, often labeled ‘not for human use,’ and exist in a regulatory gray zone that the 2026 reclassification is specifically designed to address through legitimate pharmacy channels. Purchasing them for self-injection is not FDA-compliant regardless of what you read on social media.
If a provider or website is offering peptides without requiring a consultation and prescription, that’s a red flag regardless of how the regulatory news is framing the situation.
A legitimate peptide provider in Texas will always do the following before you receive any therapy:
Peptide therapy cost in Texas varies more than most people expect, and the variation is not always about quality. It’s about overhead, delivery model, and which specific compounds you are receiving. Here’s a current breakdown.
| Cost Component | Typical Range |
| Initial physician consultation | $100-$200 (often waived or included) |
| Compounded medication (monthly) | $150-$500 depending on peptide |
| Injection supplies | $20-$50/month |
| Follow-up visits | $50-$100/session |
| IV therapy sessions (NAD+, Glutathione) | $150-$400/session |
Weight loss peptides (GLP-1 class): GLP-1 receptor agonists like semaglutide and tirzepatide are the most studied and the most expensive category. Brand-name semaglutide (Wegovy) costs approximately $1,349 per month at wholesale acquisition cost. Compounded versions typically range from $200 to $500 per month. At InjectCo, compounded semaglutide starts at $249/month and tirzepatide at $425/month through the BriteBody program.
Anti-aging and growth hormone peptides: Sermorelin is one of the most affordable, and currently fully available, growth hormone peptides. It stimulates your body’s natural growth hormone production rather than replacing it directly. Most sermorelin programs cost between $200 and $400 per month. CJC-1295/ipamorelin combination protocols were priced at $200 to $450 per month before the 2023 restrictions. These are expected to return to compounding eligibility pending the PCAC process.
NAD+ and glutathione IV therapy: These sessions typically run $150-$400 per IV infusion at a supervised clinic. Some patients receive monthly maintenance sessions; others start with a weekly series.
Skin peptides (GHK-Cu topical): Prescription compounded GHK-Cu topical formulas generally cost $80-$150/month. Injectable GHK-Cu has a separate regulatory status than topical and should be confirmed with your provider.
CJC-1295/ipamorelin is among the most searched growth hormone peptide combinations in Texas. GSC data confirms patients are actively searching ‘CJC-1295 ipamorelin clinic cost’ and related queries at significant volume. Here’s what you need to know:
In-person specialty clinics charge more, usually $300-$500/month, largely due to overhead costs, and not necessarily better medication. Some of that premium buys genuine value: hands-on guidance, in-office lab draws, and a physician who knows your specific case, while some of it is just overhead.
The delivery model also matters. Telehealth-only providers cut costs by eliminating the brick-and-mortar component. That works well for experienced patients doing self-injections at home. But for patients new to peptide therapy, especially those using IV formulations, an in-person supervised clinic offers a meaningful safety advantage.
Watch for clinics bundling peptides into expensive wellness packages that include supplements you do not need. A transparent pricing model means you know exactly what you are paying for before you commit.
This comes up constantly, and the answer is mostly no. But there are nuances worth knowing.
Certain FDA-approved peptide drugs do have insurance coverage pathways. Brand-name semaglutide (Ozempic) is covered by many commercial insurance plans for type 2 diabetes management. Tesamorelin (Egrifta) is FDA-approved for HIV-related lipodystrophy and may be covered in that specific context. These are edge cases.
For wellness-focused peptide therapy, the kind most patients at Texas medspas are pursuing, insurance coverage is not available. Compounded peptides are not FDA-approved drugs, which means they fall outside the coverage framework almost universally.
Some patients are asking whether the peptide reclassification makes these compounds insurable. It does not. Reclassification to Category 1 means licensed compounding pharmacies can legally prepare these compounds under a physician’s prescription. It does not mean these peptides are FDA-approved drugs. Insurance carriers require FDA approval and a documented medical diagnosis before covering any medication. That process takes years and has not occurred for any of the reclassified peptides.
Most Texas peptide clinics accept these payment methods:
Peptide therapy in Texas has enough providers now that comparison matters. The quality gap between a well-run physician-supervised clinic and a poorly managed wellness center is significant, and the risk is not trivial when you are dealing with injectable compounds.
| Factor | InjectCo | Typical Medspa | Telehealth-Only | Online Seller |
| Physician supervision | Yes; board-certified | Sometimes | Yes; remote | No |
| In-person care | Yes; 9 TX locations | Yes; varies | No | No |
| IV therapy (NAD+, Glutathione) | Yes | Varies | No | No |
| Custom treatment plans | Yes | Varies | Yes | No |
| Licensed compounding pharmacy | Yes | Depends | Yes | Not guaranteed |
| Home delivery option | Yes (weight loss programs) | Rarely | Yes | Yes (unregulated) |
| Regulatory transparency | Yes; explains current PCAC status | Varies | Usually | None |
| Transparent pricing | Yes; upfront | Varies | Usually | N/A |
| Follow-up protocol | Yes | Varies | Yes | No |
| Texas locations | 9 locations | 1-2 | Statewide virtual | Ships anywhere |
If you’re searching for peptides near you in Texas, access has expanded significantly across the state. InjectCo now operates across nine Texas locations.
InjectCo serves the Dallas area from its Carroll Ave location in the heart of Dallas. Patients from surrounding communities including Richardson, Garland, and Irving frequently visit for consultations and sessions.
Fort Worth and the wider Tarrant County area have strong access to physician-supervised peptide programs. InjectCo’s Colleyville location serves the mid-cities corridor and is convenient for patients from Hurst, Euless, Bedford, and Southlake.
The InjectCo Plano location inside Phenix Suites of Willow Bend serves North Dallas corridor patients from Frisco, Allen, McKinney, and surrounding communities. This is one of the highest-demand locations for weight management peptides.
InjectCo’s Argyle location serves the North DFW area, including patients from Northlake, Flower Mound, Denton, and Highland Village looking for physician-supervised peptide programs close to home.
The InjectCo Waxahachie location serves Ellis County and surrounding communities south of the DFW metroplex, including Midlothian, Ennis, and Red Oak.
InjectCo’s Cleburne location serves Johnson County and the communities south of Fort Worth, including Burleson, Joshua, and Alvarado. Patients who have previously had to travel to Fort Worth for peptide therapy now have a closer option.
InjectCo’s Austin clinic on Burnet Road offers the same physician-supervised peptide protocols as the DFW network. Austin patients searching for clinically supervised peptide therapy now have a local option backed by board-certified physician oversight.
The InjectCo Woodlands location in Shenandoah serves Houston-area patients who prefer the suburb’s accessibility. Patients from Spring, Conroe, and Kingwood regularly visit this location.
Virtual consultation and home delivery have changed how Texas patients access peptide programs. This model works particularly well for injectable peptides that patients self-administer subcutaneously at home, like sermorelin, NAD+ injections, and GLP-1 weight loss programs.
Here’s how online peptide therapy works:
InjectCo offers virtual consultations for weight management peptide programs including compounded semaglutide and tirzepatide delivery, with shipping throughout Texas.
| Factor | Online/Home Delivery | In-Clinic |
| Convenience | High (no travel required) | Lower (requires visits) |
| Cost | Often lower due to reduced overhead | Higher at full-service clinics |
| Physician supervision | Present but remote | Present and in-person |
| Administration support | Self-injection (with training) | Administered by nurse |
| IV therapy availability | Not available | Available (NAD+, glutathione) |
| Best for | Experienced patients, self-injection peptides | New patients, IV therapy, complex protocols |
This matters more than most patients realize. Peptide therapy sits at the intersection of prescribing authority, compounding pharmacy law, and clinical administration standards.
In Texas, peptide prescriptions must come from a licensed prescriber: a medical doctor (MD or DO), nurse practitioner (NP), or physician assistant (PA). Registered nurses with no prescriptive authority cannot issue peptide prescriptions independently.
Administration is a different question. Registered nurses can administer injectable peptides in a clinical setting under physician supervision. At InjectCo, every location operates under board-certified physician oversight. Licensed RN injectors handle administration of IV therapy and injectable treatments, with a physician reviewing every patient protocol.
Peptide therapy is not inherently dangerous, but unsupervised use carries real risks. Dosing errors, contaminated compounds from unregulated sources, and interactions with existing medications or conditions can all create problems. Physician supervision screens out patients who are not appropriate candidates, sets dosing based on health status, and catches problems early through scheduled follow-up.
GLP-1 receptor agonists are the dominant class here. Semaglutide and tirzepatide work by mimicking hormones that regulate appetite and insulin signaling. They slow gastric emptying, reduce hunger signals, and improve metabolic function. These are the most studied and the most clearly regulated peptide-adjacent compounds available. Both are currently accessible through InjectCo’s BriteBody program.
Sermorelin stimulates the pituitary to release growth hormone naturally. It is one of the most popular and currently fully available anti-aging peptides at Texas clinics. Results appear gradually over 3 to 6 months, including improvements in sleep, energy, muscle mass, and recovery, though individual results vary.
GHK-Cu (copper peptide) is well-supported in skin health research. It promotes collagen synthesis and supports skin repair mechanisms. The injectable form’s compounding status should be confirmed with your provider given the ongoing PCAC process. Topical compounded GHK-Cu remains available.
NAD+ supports cellular energy production and is one of the most studied compounds in the longevity space. InjectCo offers NAD+ via IV infusion and injection at all Texas locations.
Glutathione is the body’s primary antioxidant. IV glutathione supports natural detoxification pathways, immune function, and skin radiance. It is commonly stacked with NAD+ as part of a cellular health protocol.
Sermorelin, and the CJC-1295/ipamorelin combination when it returns to compounding availability, are popular with active patients for supporting lean muscle preservation and post-training recovery. Sermorelin programs currently run $200-$400/month and are fully available.
BPC-157 has been widely discussed for tissue healing and inflammation reduction. It was removed from Category 2 on April 23, 2026 and is on the July 23, 2026 PCAC agenda. Compounding availability will depend on the outcome of that review and subsequent FDA rulemaking. Consult your provider for current status.
InjectCo is Texas’s top-rated nurse-led, physician-supervised medical aesthetics and wellness company with nine locations across the state. Over 50,000 patients have been treated across the InjectCo network, with 75+ years of combined injector experience.
If you’re ready to explore what clinical peptide therapy can support for your health goals, the next step is a consultation. Book your consultation at injectco.com/premium-peptide-therapy/ or call (817) 533-7676.
Yes. Peptide therapy is legal in Texas when prescribed by a licensed physician and dispensed from a licensed 503A or 503B compounding pharmacy. The regulatory landscape has shifted significantly in 2026. Twelve peptides were formally removed from the FDA’s Category 2 restricted list on April 23, 2026, including BPC-157, TB-500, GHK-Cu (injectable), Semax, and others. However, removal from Category 2 is not the same as clearance to compound. The FDA’s PCAC is scheduled to review seven of these peptides on July 23-24, 2026, and formal rulemaking must follow. Always ask your provider which compounds are currently available from a compliant compounding pharmacy.
Mostly no. Brand-name FDA-approved peptide drugs (like semaglutide for diabetes) may be covered depending on your plan and diagnosis. Compounded peptides prescribed for wellness purposes are almost universally self-pay. The 2026 reclassification does not create insurance coverage; that requires full FDA drug approval, which none of the reclassified peptides have completed. HSA and FSA accounts can often be used, and financing options including CareCredit and Cherry are available at InjectCo.
Partially. BPC-157 was removed from the FDA’s Category 2 restricted list on April 23, 2026. However, that is not the same as being cleared for compounding. The FDA’s PCAC is scheduled to review BPC-157 on July 23, 2026. After the meeting, the FDA must complete formal rulemaking before licensed compounding pharmacies can legally prepare and dispense BPC-157 under physician prescription. If a provider today is offering BPC-157 from a compounding pharmacy, ask them to explain the specific regulatory basis. The compliant answer as of June 2026 is that availability is still pending.
InjectCo offers physician-supervised peptide therapy at nine Texas locations: Dallas, Fort Worth (Colleyville), Plano, Argyle, Waxahachie, Cleburne, The Woodlands, and Austin. Virtual consultations are also available for weight management peptide programs with home delivery throughout Texas.
It depends on the peptide and delivery model. Compounded weight loss peptides like semaglutide start around $249/month and tirzepatide around $425/month at InjectCo. Sermorelin typically runs $200-$400/month. NAD+ IV therapy ranges from $150-$400 per session. A physician consultation is required before any pricing is confirmed.
Both are growth hormone secretagogues; they stimulate your pituitary to produce more growth hormone rather than replacing it. Sermorelin is currently fully available from licensed compounding pharmacies. CJC-1295 and ipamorelin are expected to return to compounding eligibility pending the 2026 PCAC process. Sermorelin has a shorter half-life and is typically dosed daily. The CJC-1295/ipamorelin combination has a longer half-life and is often dosed several times per week. Your provider can help you determine which protocol fits your goals and timeline.
Compounded peptides prescribed by a licensed physician can be delivered to your home through a licensed pharmacy, and some Texas clinics, including InjectCo, offer this for weight management programs. What you should not do is purchase research peptides online without a prescription. These are not manufactured under medical-grade quality controls and are not legal for human use. The April 2026 reclassification news has led some online sellers to market previously restricted compounds as newly legal, but as of June 2026, compounding pharmacy access for most of these compounds is still pending formal rulemaking.
It varies by peptide and goal. GLP-1 weight loss programs often show results within the first 4-8 weeks. Sermorelin and growth hormone secretagogues typically show gradual improvements in sleep, energy, and body composition over 3-6 months. NAD+ and glutathione IV therapy can produce more immediate effects in energy and cognitive clarity for some patients.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptide therapies referenced in this article have not been evaluated by the Food and Drug Administration for the wellness indications described. These therapies are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always consult a licensed physician before starting any peptide therapy program. Not all patients are candidates for all treatments. Regulatory information reflects the situation as of June 23, 2026; confirm current compound availability with your provider.
